Zoetis receives FDA approval for heartworm disease treatment

DIROBAN uses melarsomine dihydrochloride to treat heartworm disease

Zoetis has announced that its heartworm treatment DIROBAN has received approval from the U.S. Food and Drug Administration (FDA). DIROBAN (melarsomine dihydrochloride) is for treatment of dogs infected with Dirofilaria omits — the cause of heartworm disease. It is now available for sale to veterinarians in the United States.

Melarsomine dihydrochloride, the preferred method for treating canine heartworm disease, is recommended by both the American Heartworm Society and the Companion Animal Parasite Council. With shortages of other heartworm treatments that used Melarsomine dihydrochloride, Zoetis decided to introduce DIROBAN to the market.

“Every dog that tests positive for heartworm disease should have access to the best treatment,” said Shelley Stanford, DVM, the group director of the companion animal veterinary professional services at Zoetis. “Veterinarians can now depend on Zoetis and DIROBAN for the treatment of heartworm disease in their patients. This is one more example of our commitment to help pet owners and the dogs they love receive the standard of care that is best for long-term health.”

For more information about Diroban, visit the Zoetis website.

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *